Anchor position verification for prosthetic cardiac valve devices

Information

  • Patent Grant
  • 12201521
  • Patent Number
    12,201,521
  • Date Filed
    Tuesday, March 22, 2022
    2 years ago
  • Date Issued
    Tuesday, January 21, 2025
    15 days ago
Abstract
A device for treating a diseased native valve in a patient is provided, the device including a frame structure and a plurality of leaflets. The device can further include a spiral anchor configured to extend around an outer circumference of the frame structure. The anchor can be configured to deliver a contrast agent into or near a target tissue. Other embodiments and methods of use are also provided.
Description
BACKGROUND

Blood flow between heart chambers is regulated by native valves—the mitral valve, the aortic valve, the pulmonary valve, and the tricuspid valve. Each of these valves is a passive one-way valve that opens and closes in response to differential pressures. Patients with valvular disease have abnormal anatomy and/or function of at least one valve. For example, a valve may suffer from insufficiency, also referred to as regurgitation, when the valve does not fully close, thereby allowing blood to flow retrograde. Valve stenosis can cause a valve to fail to open properly. Other diseases may also lead to dysfunction of the valves.


The mitral valve, for example, sits between the left atrium and the left ventricle and, when functioning properly, allows blood to flow from the left atrium to the left ventricle while preventing backflow or regurgitation in the reverse direction. Native valve leaflets of a diseased mitral valve, however, do not fully prolapse, causing the patient to experience regurgitation.


While medications may be used to treat diseased native valves, the defective valve often needs to be repaired or replaced at some point during the patient's lifetime. Existing prosthetic valves and surgical repair and/or replacement procedures may have increased risks, limited lifespans, and/or are highly invasive. Some less invasive transcatheter options are available, but most are not ideal. A major limitation of existing transcatheter mitral valve devices, for example, is that the mitral valve devices are too large in diameter to be delivered transseptally, requiring transapical access instead. Furthermore, existing mitral valve replacement devices are not optimized with respect to strength-weight ratio and often take up too much space within the valve chambers, resulting in obstruction of outflow from the ventricle into the aorta and/or thrombosis.


At times, fixation of a valve replacement device to the native anatomy is achieved using an anchor structure that is delivered transcatheter. It can be a challenge for clinicians to confirm that the anchor is properly positioned with respect to the native anatomy during implantation, e.g., due to the size and materials used to construct anchors that are suitable for minimally invasive implantation.


Thus, a new valve device that overcomes some or all of these deficiencies is desired.


SUMMARY OF THE DISCLOSURE

A prosthesis for treating a diseased native valve is provided, the prosthesis comprising a frame structure having a plurality of leaflets therein, and a spiral anchor configured to extend around an outer perimeter of the frame structure, comprising a wall defining a lumen, and at least one port in fluid communication with the lumen, the lumen and the at least one port shaped and sized to transport and deliver a contrast agent that is detectable by a visualization modality.


In additional embodiments, the wall defining the lumen is an interior wall within an outer perimeter of the spiral anchor.


In other embodiments, the wall defining the lumen is continuous from a proximal end to a distal end of the spiral anchor.


In some embodiments, the wall defining the lumen is an exterior wall along an outer perimeter of the spiral anchor (e.g., a monorail).


In some embodiments, a proximal end of the wall is configured to fluidly couple with a distal end of a contrast agent delivery catheter, during the delivery of the prosthesis.


In some embodiments, the at least one port is at a distal tip of the anchor.


In additional embodiments, the at least one port is proximal to a distal tip of the anchor.


In some embodiments, the at least one port is oriented toward a leaflet and/or an annulus of the diseased native valve, when the spiral anchor is near a delivery position with respect to the diseased native valve.


In other embodiments, the delivery position is a sub-annular space of the diseased native valve.


In some embodiments, the contrast agent comprises barium-sulfate, iodine, or an iodine-based material.


A method of delivering a valve prosthesis is provided, comprising advancing a distal end of a delivery device to a first side of a native valve, deploying an anchor from a delivery configuration to a deployed configuration on the first side of the native valve, the anchor comprising at least one port for delivering a contrast agent therefrom, advancing the anchor in the deployed configuration from the first side of the native valve to a second side of the native valve, rotating the anchor in the deployed configuration around one or more structures on the second side of the native valve, delivering the contrast agent through the at least one port, identifying a characteristic of the contrast agent in an image to confirm that the anchor has been rotated around the one or more structures.


In additional embodiments, the method includes releasing the anchor from the distal end of the delivery device.


In some embodiments, delivering the contrast agent comprises delivering into a blood flow path of the heart.


In some embodiments, delivering the contrast agent comprises delivering following the step of advancing to the second side of the native valve.


In other embodiments, the characteristic of the contrast agent comprises an extent of dispersion.


In some embodiments, confirming that the anchor has been fully rotated comprises confirming that dispersion of the contrast agent is substantially confined to a selected region.


In some embodiments, the selected region comprises a sub-annular space of the native valve.


In some embodiments, the method further comprises repeating at least one of the rotating, delivering, and identifying steps until the extent of dispersion is within the selected region.


In other embodiments, the image comprises a fluoroscopic image.


In additional embodiments, the anchor comprises the anchor of claim 1.





BRIEF DESCRIPTION OF THE DRAWINGS


FIGS. 1A-1B show an exemplary valve prosthesis (also referred to herein as “valve device”) for replacement of a valve, such as a mitral valve.



FIGS. 2A-2H show sequential views of an exemplary method of implanting a valve prosthesis.



FIGS. 3A-3C illustrate one embodiment of an anchor that can include one or more structures that are adapted to transport and deliver a contrast agent.



FIGS. 4A-4B illustrate visualization of a contrast agent delivered by an anchor.



FIG. 5 is a flowchart describing a method of delivering contrast agent with an anchor of a valve replacement device.





DETAILED DESCRIPTION

Described herein are systems, devices, or methods for treatment or replacement of a diseased native valve of the heart, for example a mitral valve.



FIGS. 1A-1B show an exemplary valve prosthesis 10 (also referred to herein as “valve device”) for replacement of a valve, such as a mitral valve. The illustrated valve prosthesis 10 comprises a frame structure 12, leaflets 14, and an anchor 15. The anchor 15 includes a wire 20 formed in a spiral shape around the frame structure 12.


The exemplary frame structure 12 is configured like a stent. The frame structure 12 has an expanded state and an unexpanded (e.g., collapsed or compressed) state. The compressed state is sized and dimensioned for percutaneous insertion and the expanded state is sized and dimensioned for implantation in a native valve of a patient, such as a mitral valve.


The anchor 15 can include a spiral member, such as wire 20, having a proximal end 21 and a distal end 22. The anchor 15 can be configured to engage with the frame structure 12 via a compression fit. The wire 20 can be formed of a material having sufficient rigidity to hold a predetermined shape. In an exemplary embodiment, the wire 20 can be formed of a shape memory material (e.g. NiTi). Further, the anchor 15 prior to implantation may comprise a flat spiral shape such that loops of the anchor are generally positioned within the same plane (the plane being perpendicular to a longitudinal axis of a delivery device). Additionally, in some embodiments, the distal end 22 can be rounded and/or atraumatic.


The valve prosthesis 10 can be configured for replacing a mitral valve with the distal end 22 configured for insertion through a commissure.



FIGS. 2A-2H show sequential views of an exemplary method of implanting a valve prosthesis 10. At FIG. 2A, a transseptal puncture is made. A guidewire 54 is then routed through the puncture site and left either in the left atrium 25 or across the mitral valve into the left ventricle 26. At FIG. 2B, the outer sheath 50 (optionally with an inner dilator 51) is tracked over the guidewire 54 until the distal end of the outer sheath 50 protrudes into the left atrium 25. The guidewire 54 and inner dilator 51 are then removed from the outer sheath 50. At FIG. 2C, an inner shaft and attached distal anchor guide 153 are inserted through the outer sheath 50 until the distal tip of the anchor guide 153 extends into the left atrium 25. The anchor guide 153 can be positioned and/or oriented as desired by steering the distal end of the sheath 50 and/or rotating the inner shaft and anchor guide 153 relative to the sheath 50. At FIG. 2D, once the anchor guide 153 is in the correct orientation, the anchor 15 can be pushed out through distal tip of the anchor guide 153 (with the distal tip 22 extending out of the guide 153 first). At FIG. 2E, the anchor 15 can fully deploy into the atrium 25. At FIG. 2F, the entire delivery system 30 can be pushed and steered (for example, via steering mechanisms in the outer sheath 50) towards an apex of the ventricle 26, crossing through the mitral valve. In some embodiments, counter-rotation of the anchor 15 may aid in getting the anchor 15 across the mitral valve without tangling. Once the anchor 15 is at the correct depth within the ventricle 26, forward rotation of the anchor 15 (via forward rotation of the inner shaft and guide 153) will allow the anchor 15 to encircle the mitral leaflets and chordae (i.e., with the distal end 22 leading the encircling). At FIG. 2G, the outer sheath 40, inner sheath, and anchor guide 153 are removed, leaving a tether 78 in place (and attached to the proximal end 21 of the anchor 15). Next, the frame structure 12 can then be delivered over the tether 78 and into place within the anchor 15. At FIG. 2H, the frame structure 12 has been delivered, the tether 78 has been released from the proximal end 21 of the anchor 15 to leave the prosthesis 10 in place in the mitral valve 4. As shown in the exemplary FIG. 2H, the anchor 15 is positioned to encircle substantially all of the chordae 42 and is “high” in the ventricle 26. An anchor 15 that has a high position can be adjacent the inferior surface of the annulus of mitral valve 4.


In some embodiments, an anchor 15 is adapted to transport and deliver a biocompatible contrast agent that can enhance an imaging modality image during and/or following delivery of the anchor. The imaging modality can be any modality that is compatible with minimally invasive procedures, such as fluoroscopy and/or echocardiography. Examples of contrast agents (e.g., media) comprise iodine, iodine-based compounds, barium-sulfate, or saline. Without being bound by theory, regarding an x-ray imagining modality, the contrast agent can block or limit the passage of x-rays therethrough. Regarding an ultrasound imaging modality, the contrast agent may possess an increased echogenicity. An anchor 15 that delivers such a contrast agent during and/or following its deployment can alter the appearance of the heart anatomy and/or of the circulation therein, for example of one or more chambers or vessels of the heart.


Referring to FIGS. 3A-3C, in some embodiments, the anchor 15 can include one or more structures that are adapted to transport and deliver a contrast agent 120 from a contrast agent source 135 through the anchor and into or near a target tissue or anatomy of the patient (such as a heart). FIG. 3A depicts an entirety of the anchor 15, including a distal tip (further illustrated in FIG. 3B) and portions of the anchor proximal to the tip (further illustrated in FIG. 3C). It should be noted that in the illustrated embodiment, the distal portion of the anchor 15 can have a larger radius of curvature compared to other, more proximal portions of the anchor, causing the distal portion to extend or “stick out” from the rest of the anchor. It should be understood that other embodiments of the anchor may not have this distal portion that extends outwards, and can instead comprise an anchor that has only a single radius of curvature (such as the anchor depicted in FIG. 1A).


The contrast agent source 135 can be a vessel, container, or volume either disposed within the anchor 15 or remote from the anchor. The contrast agent source 135 is fluidly coupled with the lumen 130 of the anchor. In some embodiments, the contrast agent source can be a syringe exterior to the anchor and to the patient. In other embodiments, the lumen of the anchor can be fluidly coupled to another lumen within a delivery catheter, and the contrast agent source can be either fluidly coupled to the delivery catheter lumen or remote from (but fluidly coupled to) the delivery catheter. The contrast agent source can further include a mechanism for delivering contrast agent from the source into the lumen(s) and out through the port(s) of the anchor. For example, in one embodiment the contrast agent can be delivered by deploying a syringe. In other embodiments, pumps or other ways of pressurizing and/or creating a flow of the contrast agent can be implemented.


As depicted in the example FIG. 3B, in some embodiments, the contrast agent 120 is delivered from a tip of the anchor 15, which comprises a lumen 130 and one or more ports 125. In some embodiments, the lumen 130 is formed by an inner wall of the anchor 15 that is located within an outer perimeter of the anchor (e.g., is substantially centrally located). In some embodiments, the lumen 130 is formed by an outer wall of the anchor 15 (e.g., as a monorail). The lumen 130 can traverse from a proximal portion to a distal portion of the anchor 15. In some embodiments that comprise a monorail construction, the lumen may traverse less than the entirety of the length of the anchor 15. For example, a proximal end of the lumen 130 may terminate distal to a proximal end of the anchor 15, and/or a distal end of the lumen 130 may terminate proximal to a distal end of the anchor 15.


As depicted in the example FIG. 3C, in some embodiments, the contrast agent 120 is delivered from one or more portions of the anchor 15 that are proximal to the tip, where the proximal portions include a lumen 110 and one or more ports 115. In some embodiments, the one or more ports 115 are positioned on the body of the anchor 15 such that, when delivered in a selected orientation and/or position in the heart, the one or more ports 115 are at least partially obstructed by one or more portions of the native heart. For example, an obstruction can comprise a leaflet of the native valve, one or more chordae, an inferior surface of the valve annulus, or a portion of the ventricular heart wall. In some embodiments, the one or more ports 115 are oriented to be generally radially-outward, generally radially-inward, and/or generally along a superior aspect of the anchor 15 (e.g., superior when implanted in the ventricle of the heart).


In some embodiments, feedback regarding an orientation and/or position of the anchor 15 with respect to the native heart anatomy can be provided according to one or more characteristics of the blood flow, visualized in the presence of the contrast agent that is delivered via the anchor 15. Within a ventricle of the heart, blood flow velocity is often reduced in a region that is inferior and peripheral to the valve annulus. In contrast, blood flow velocity within the ventricle is increased within a central region of the chamber, moving toward the apex of the heart. Referring now to FIGS. 4A-4B, in some embodiments an anchor 15 that is position “low” with respect to the sub-annular tissue (e.g., anchor 140 seen in cross-section, FIG. 4B) may release contrast agent 120 into a space having a relatively high blood flow velocity, such that the contrast agent 120 dilutes and/or disperses relatively quickly. The contrast agent 120 may appear to have a reduced or diminished intensity in such a condition, and/or to occupy a greater region of space within the heart. Referring now to FIGS. 4C-D, in some embodiments, an anchor 15 that is positioned in a preferred “high” near the sub-annular tissue (e.g., anchor 150 seen in cross-section, FIG. 4D) may release contrast agent 120 into a space having a relatively low blood flow velocity, such that the contrast agent 120 gathers in the space with little dilution and/or dispersion. The contrast agent 120 may appear to have a greater intensity with the given imaging modality in such a condition. In combination with an appropriate imaging modality, the position of the anchor 15 can be (e.g., indirectly) measured or confirmed by the intensity and/or dispersion of a contrast agent 120.



FIG. 5 is a flowchart that describes a method of delivering a valve prosthesis including delivering a contrast agent with an anchor of a valve prosthesis. In some embodiments, at step 502, the method can include advancing a distal end of a delivery device to a first side of a native valve (FIG. 2C). At step 504, the method can further include deploying an anchor from a delivery configuration to a deployed configuration on the first side of the native valve (FIG. 2D-FIG. 2E). In some embodiments, the anchor can comprise at least one port for delivering a contrast agent therefrom. At step 506, the method can further include advancing the anchor in the deployed configuration from the first side of the native valve to a second side of the native valve and at step 508, rotating the anchor in the deployed configuration around one or more structures on the second side of the native valve (FIG. 2F). At step 510, the method can include delivering the contrast agent through the at least one port (as shown in FIGS. 3A-3C). Finally, the method can include identifying a characteristic of the contrast agent in an image to confirm that the anchor has been rotated around the one or more structures.


In some embodiments, the method of FIG. 5 can further include releasing the anchor from the distal end of the delivery device.


In some embodiments, delivering the contrast agent comprises delivering into a blood flow path of the heart. In other embodiments, delivering the contrast agent comprises delivering following the step of advancing to the second side of the native valve.


In some examples, the characteristic of the contrast agent comprises an extent of dispersion. In one implementation, confirming that the anchor has been fully rotated comprises confirming that dispersion of the contrast agent is substantially confined to a selected region.


In some examples, the selected region comprises a sub-annular space of the native valve.


In some implementations of the method, the method further includes repeating at least one of the rotating, delivering, and identifying steps until the extent of dispersion is within the selected region.


In some examples, the image comprises a fluoroscopic image.


In other embodiments, the anchor comprises any of the anchors described in this disclosure.


Additional elements of valve prostheses, anchors, and methods of delivery are described in PCT Application No. PCT/US2019/047542 filed on Aug. 21, 2019, PCT Application No. PCT/US2019/057082 filed on Mar. 19, 2019, PCT Application No. PCT/US2019/068088 filed on Dec. 20, 2019, and PCT Application No. PCT/US2020/23671, the entireties of which are incorporated by reference herein in their entireties.


It should be understood that any feature described herein with respect to one embodiment can be substituted for or combined with any feature described with respect to another embodiment.


When a feature or element is herein referred to as being “on” another feature or element, it can be directly on the other feature or element or intervening features and/or elements may also be present. In contrast, when a feature or element is referred to as being “directly on” another feature or element, there are no intervening features or elements present. It will also be understood that, when a feature or element is referred to as being “connected”, “attached” or “coupled” to another feature or element, it can be directly connected, attached or coupled to the other feature or element or intervening features or elements may be present. In contrast, when a feature or element is referred to as being “directly connected”, “directly attached” or “directly coupled” to another feature or element, there are no intervening features or elements present. Although described or shown with respect to one embodiment, the features and elements so described or shown can apply to other embodiments. It will also be appreciated by those of skill in the art that references to a structure or feature that is disposed “adjacent” another feature may have portions that overlap or underlie the adjacent feature.


Terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. For example, as used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. It will be further understood that the terms “comprises” and/or “comprising,” when used in this specification, specify the presence of stated features, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, steps, operations, elements, components, and/or groups thereof. As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items and may be abbreviated as “/”.


Spatially relative terms, such as “under”, “below”, “lower”, “over”, “upper” and the like, may be used herein for ease of description to describe one element or feature's relationship to another element(s) or feature(s) as illustrated in the figures. It will be understood that the spatially relative terms are intended to encompass different orientations of the device in use or operation in addition to the orientation depicted in the figures. For example, if a device in the figures is inverted, elements described as “under” or “beneath” other elements or features would then be oriented “over” the other elements or features. Thus, the exemplary term “under” can encompass both an orientation of over and under. The device may be otherwise oriented (rotated 90 degrees or at other orientations) and the spatially relative descriptors used herein interpreted accordingly. Similarly, the terms “upwardly”, “downwardly”, “vertical”, “horizontal” and the like are used herein for the purpose of explanation only unless specifically indicated otherwise.


Although the terms “first” and “second” may be used herein to describe various features/elements (including steps), these features/elements should not be limited by these terms, unless the context indicates otherwise. These terms may be used to distinguish one feature/element from another feature/element. Thus, a first feature/element discussed below could be termed a second feature/element, and similarly, a second feature/element discussed below could be termed a first feature/element without departing from the teachings of the present invention.


Throughout this specification and the claims which follow, unless the context requires otherwise, the word “comprise”, and variations such as “comprises” and “comprising” means various components can be co-jointly employed in the methods and articles (e.g., compositions and apparatuses including device and methods). For example, the term “comprising” will be understood to imply the inclusion of any stated elements or steps but not the exclusion of any other elements or steps.


As used herein in the specification and claims, including as used in the examples and unless otherwise expressly specified, all numbers may be read as if prefaced by the word “about” or “approximately,” even if the term does not expressly appear. The phrase “about” or “approximately” may be used when describing magnitude and/or position to indicate that the value and/or position described is within a reasonable expected range of values and/or positions. For example, a numeric value may have a value that is +/−0.1% of the stated value (or range of values), +/−1% of the stated value (or range of values), +/−2% of the stated value (or range of values), +/−5% of the stated value (or range of values), +/−10% of the stated value (or range of values), etc. Any numerical values given herein should also be understood to include about or approximately that value, unless the context indicates otherwise. For example, if the value “10” is disclosed, then “about 10” is also disclosed. Any numerical range recited herein is intended to include all sub-ranges subsumed therein. It is also understood that when a value is disclosed that “less than or equal to” the value, “greater than or equal to the value” and possible ranges between values are also disclosed, as appropriately understood by the skilled artisan. For example, if the value “X” is disclosed the “less than or equal to X” as well as “greater than or equal to X” (e.g., where X is a numerical value) is also disclosed. It is also understood that the throughout the application, data is provided in a number of different formats, and that this data, represents endpoints and starting points, and ranges for any combination of the data points. For example, if a particular data point “10” and a particular data point “15” are disclosed, it is understood that greater than, greater than or equal to, less than, less than or equal to, and equal to 10 and 15 are considered disclosed as well as between 10 and 15. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.


While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.

Claims
  • 1. A prosthesis for treating a diseased native valve, the prosthesis comprising: a frame structure having a plurality of leaflets therein; anda spiral anchor configured to extend around an outer perimeter of the frame structure, comprising a wall defining a lumen that is an exterior wall along an outer perimeter of the spiral anchor (e.g., a monorail), andat least one port in fluid communication with the lumen,the lumen and the at least one port shaped and sized to transport and deliver a contrast agent that is detectable by a visualization modality.
  • 2. The prosthesis of claim 1, wherein the wall defining the lumen is an interior wall within an outer perimeter of the spiral anchor.
  • 3. The prosthesis of claim 2, wherein the wall defining the lumen is continuous from a proximal end to a distal end of the spiral anchor.
  • 4. The prosthesis of claim 1, wherein a proximal end of the wall is configured to fluidly couple with a distal end of a contrast agent delivery catheter, during the delivery of the prosthesis.
  • 5. The prosthesis of claim 1, wherein the at least one port is at a distal tip of the anchor.
  • 6. The prosthesis of claim 1, wherein the at least one port is proximal to a distal tip of the anchor.
  • 7. The prosthesis of claim 1, wherein the at least one port is oriented toward a leaflet and/or an annulus of the diseased native valve, when the spiral anchor is near a delivery position with respect to the diseased native valve.
  • 8. The prosthesis of claim 7, wherein the delivery position is a sub-annular space of the diseased native valve.
  • 9. The prosthesis of claim 1, wherein the contrast agent comprises barium-sulfate, iodine, or an iodine-based material.
  • 10. A method of delivering a valve prosthesis, comprising: advancing a distal end of a delivery device to a first side of a native valve;deploying an anchor from a delivery configuration to a deployed configuration on the first side of the native valve, the anchor comprising at least one port for delivering a contrast agent therefrom;advancing the anchor in the deployed configuration from the first side of the native valve to a second side of the native valve;rotating the anchor in the deployed configuration around one or more structures on the second side of the native valve;delivering the contrast agent through the at least one port into a blood flow path of the heart;identifying a characteristic of the contrast agent in an image to confirm that the anchor has been rotated around the one or more structures.
  • 11. The method of claim 10, further comprising releasing the anchor from the distal end of the delivery device.
  • 12. The method of claim 10, wherein delivering the contrast agent comprises delivering following the step of advancing to the second side of the native valve.
  • 13. The method of claim 12, wherein confirming that the anchor has been fully rotated comprises confirming that dispersion of the contrast agent is substantially confined to a selected region.
  • 14. The method of claim 11, wherein the characteristic of the contrast agent comprises an extent of dispersion.
  • 15. The method of claim 14, wherein the selected region comprises a sub-annular space of the native valve.
  • 16. The method of claim 14, further comprising repeating at least one of the rotating, delivering, and identifying steps until the extent of dispersion is within the selected region.
  • 17. The method of claim 10, wherein the image comprises a fluoroscopic image.
CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 63/164,514, filed Mar. 22, 2021, which is herein incorporated by reference in its entirety.

US Referenced Citations (616)
Number Name Date Kind
4725274 Lane et al. Feb 1988 A
5002563 Pyka et al. Mar 1991 A
5327905 Avitall Jul 1994 A
5356424 Buzerak et al. Oct 1994 A
5370685 Stevens Dec 1994 A
5582616 Bolduc et al. Dec 1996 A
5716397 Myers Feb 1998 A
5755601 Jones May 1998 A
5779669 Haissaguerre et al. Jul 1998 A
5873835 Hastings et al. Feb 1999 A
5944690 Falwell et al. Aug 1999 A
5997526 Giba et al. Dec 1999 A
6048339 Zirps et al. Apr 2000 A
6053873 Govari et al. Apr 2000 A
6254550 McNamara et al. Jul 2001 B1
6419695 Gabbay Jul 2002 B1
6419696 Ortiz Jul 2002 B1
6530952 Vesely Mar 2003 B2
6533783 Töllner Mar 2003 B1
6641553 Chee et al. Nov 2003 B1
6752813 Goldfarb et al. Jun 2004 B2
6908478 Alferess et al. Jun 2005 B2
6964684 Ortiz et al. Nov 2005 B2
6974476 McGuckin, Jr. et al. Dec 2005 B2
7077861 Spence Jul 2006 B2
7101395 Tremulis et al. Sep 2006 B2
7125421 Tremulis et al. Oct 2006 B2
7160322 Gabbay Jan 2007 B2
7175656 Khairkhahan Feb 2007 B2
7201771 Lane Apr 2007 B2
7226467 Lucatero et al. Jun 2007 B2
7381219 Salahieh et al. Jan 2008 B2
7329279 Haug et al. Feb 2008 B2
7445631 Salahieh et al. Nov 2008 B2
7470285 Nugent et al. Dec 2008 B2
7527647 Spence May 2009 B2
7534261 Freidman May 2009 B2
7563267 Goldfarb et al. Jul 2009 B2
7594903 Webler et al. Sep 2009 B2
7604646 Goldfarb et al. Oct 2009 B2
7608091 Goldfarb et al. Oct 2009 B2
7618449 Tremulis et al. Nov 2009 B2
7621948 Herrmann et al. Nov 2009 B2
7666204 Thornton et al. Feb 2010 B2
7704269 St. Goar et al. Apr 2010 B2
7731705 Wardle Jun 2010 B2
7748389 Salahich et al. Jul 2010 B2
7749266 Forster et al. Jul 2010 B2
7780725 Haug et al. Aug 2010 B2
7799069 Bailey et al. Sep 2010 B2
7811296 Goldfarb et al. Oct 2010 B2
7824442 Salahieh et al. Nov 2010 B2
7824443 Salahieh et al. Nov 2010 B2
7846203 Cribier Dec 2010 B2
7942927 Kaye May 2011 B2
7947075 Goetz et al. May 2011 B2
7951195 Antonsson et al. May 2011 B2
7959666 Salahieh et al. Jun 2011 B2
7988724 Salahleh et al. Aug 2011 B2
8021421 Fogarty et al. Sep 2011 B2
8052749 Salahieh et al. Nov 2011 B2
8052750 Tuval et al. Nov 2011 B2
8062355 Figulla et al. Nov 2011 B2
8070800 Lock et al. Dec 2011 B2
8075615 Eberhardt et al. Dec 2011 B2
8096985 Legaspi et al. Jan 2012 B2
8147541 Forster et al. Apr 2012 B2
8147542 Maisano et al. Apr 2012 B2
8182528 Salahleh et al. May 2012 B2
8216256 Raschdorf et al. Jul 2012 B2
8236049 Rowe et al. Aug 2012 B2
8241351 Cabiri Aug 2012 B2
8251977 Partlett Aug 2012 B2
8252050 Maisano et al. Aug 2012 B2
8287584 Salahleh et al. Oct 2012 B2
8313526 Hoffman et al. Nov 2012 B2
8323241 Salahich et al. Dec 2012 B2
8323336 Hill et al. Dec 2012 B2
8328868 Paul et al. Dec 2012 B2
8343213 Salahleh et al. Jan 2013 B2
8348995 Tuval et al. Jan 2013 B2
8348996 Tuval et al. Jan 2013 B2
8366767 Zhang Feb 2013 B2
8403981 Forster et al. Mar 2013 B2
8403983 Quadri et al. Mar 2013 B2
8414643 Tuval et al. Apr 2013 B2
8414644 Quadri et al. Apr 2013 B2
8414645 Dwork et al. Apr 2013 B2
8425593 Braido et al. Apr 2013 B2
8449599 Chau et al. May 2013 B2
8454686 Alkhatib Jun 2013 B2
8465541 Dwork Jun 2013 B2
8500800 Maisano et al. Aug 2013 B2
8512401 Murray et al. Aug 2013 B2
8523881 Cabiri et al. Sep 2013 B2
8545553 Zipory et al. Oct 2013 B2
8556963 Tremulis et al. Oct 2013 B2
8562645 Stone et al. Oct 2013 B2
8562673 Yeung et al. Oct 2013 B2
8579962 Salahleh et al. Nov 2013 B2
8603157 Seguin et al. Dec 2013 B2
8603160 Salahieh et al. Dec 2013 B2
8623075 Murray et al. Jan 2014 B2
8628570 Seguin Jan 2014 B2
8641727 Starksen et al. Feb 2014 B2
8652202 Alon et al. Feb 2014 B2
8652203 Quadri et al. Feb 2014 B2
8657872 Seguin Feb 2014 B2
8663322 Keranen Mar 2014 B2
8685086 Navia et al. Apr 2014 B2
8696693 Najafi et al. Apr 2014 B2
8715342 Zipory et al. May 2014 B2
8740976 Tran et al. Jun 2014 B2
8784479 Antonsson et al. Jul 2014 B2
8790367 Nguyen et al. Jul 2014 B2
8808368 Maisano et al. Aug 2014 B2
8828078 Salahieh et al. Sep 2014 B2
8834564 Tuval et al. Sep 2014 B2
8840663 Salahieh et al. Sep 2014 B2
8840664 Karapetian et al. Sep 2014 B2
8845588 Bruszewski Sep 2014 B2
8852271 Murray et al. Oct 2014 B2
8876893 Dwork et al. Nov 2014 B2
8876894 Tuval et al. Nov 2014 B2
8876895 Tuval et al. Nov 2014 B2
8900294 Paniagua et al. Dec 2014 B2
8911494 Hammer et al. Dec 2014 B2
8920369 Salahieh et al. Dec 2014 B2
8926690 Kowalsky Jan 2015 B2
8926696 Cabiri et al. Jan 2015 B2
8926697 Gross et al. Jan 2015 B2
8940002 Goertzen Jan 2015 B2
8940044 Hammer et al. Jan 2015 B2
8951299 Paul et al. Feb 2015 B2
8986371 Quill et al. Mar 2015 B2
8998980 Shipley et al. Apr 2015 B2
9005273 Salahleh et al. Apr 2015 B2
9011515 Schweich et al. Apr 2015 B2
9011523 Seguin Apr 2015 B2
9011530 Reich et al. Apr 2015 B2
9017408 Siegal et al. Apr 2015 B2
9023100 Quadri et al. May 2015 B2
9034032 McLean et al. May 2015 B2
9039757 McLean et al. May 2015 B2
9056009 Keränen Jun 2015 B2
9061120 Osypka et al. Jun 2015 B2
9095431 Yu et al. Aug 2015 B2
9119719 Zipory et al. Sep 2015 B2
9125739 Paniagua et al. Sep 2015 B2
9125740 Morriss et al. Sep 2015 B2
9155619 Liu et al. Oct 2015 B2
9168129 Valdez et al. Oct 2015 B2
9168131 Yohanan et al. Oct 2015 B2
9173713 Hart et al. Nov 2015 B2
9173737 Hill et al. Nov 2015 B2
9180006 Keränen Nov 2015 B2
9226823 Dwork Jan 2016 B2
9232995 Kovalsky et al. Jan 2016 B2
9277994 Miller et al. Mar 2016 B2
9289297 Wilson Mar 2016 B2
9295547 Costello et al. Mar 2016 B2
9301756 Wardle Apr 2016 B2
9301836 Buchbinder et al. Apr 2016 B2
9320597 Savage et al. Apr 2016 B2
9343224 Zilbershlag May 2016 B2
9358110 Paul et al. Jun 2016 B2
9414915 Lombardi et al. Aug 2016 B2
9427315 Schweich et al. Aug 2016 B2
9439757 Wallace et al. Sep 2016 B2
9468525 Kovalsky Oct 2016 B2
9474606 Zipory Oct 2016 B2
9474840 Siess Oct 2016 B2
9480559 Vidlund et al. Nov 2016 B2
9492273 Wallace et al. Nov 2016 B2
9526487 Rahmani Dec 2016 B2
9526609 Salahieh et al. Dec 2016 B2
9532868 Braido Jan 2017 B2
9532870 Cooper et al. Jan 2017 B2
9561102 Rust et al. Feb 2017 B2
9579198 Deem et al. Feb 2017 B2
9636224 Zipory et al. May 2017 B2
9636481 Campbell et al. May 2017 B2
9662202 Quill et al. May 2017 B2
9662206 Börtlein et al. May 2017 B2
9662209 Gross et al. May 2017 B2
9675454 Vidlund et al. Jun 2017 B2
9681952 Hacohen et al. Jun 2017 B2
9687343 Börtlein et al. Jun 2017 B2
9724192 Sheps et al. Aug 2017 B2
9730790 Quadri et al. Aug 2017 B2
9730793 Reich et al. Aug 2017 B2
9744031 Girard et al. Aug 2017 B2
9744038 Dahlgren et al. Aug 2017 B2
9750605 Ganesan et al. Sep 2017 B2
9763779 Börtlein et al. Sep 2017 B2
9763780 Morriss et al. Sep 2017 B2
9814611 Cartledge et al. Nov 2017 B2
9827090 Hill et al. Nov 2017 B2
9861480 Zakai et al. Jan 2018 B2
9867700 Bakis et al. Jan 2018 B2
9867702 Keränen et al. Jan 2018 B2
9877833 Bishop et al. Jan 2018 B1
9883941 Hastings et al. Feb 2018 B2
9889003 Börtlein Feb 2018 B2
9895221 Vidlund Feb 2018 B2
9895222 Zeng et al. Feb 2018 B2
9901444 Valdez et al. Feb 2018 B2
9918840 Reich et al. Mar 2018 B2
D815744 Ratz et al. Apr 2018 S
9949825 Braido et al. Apr 2018 B2
9949828 Sheps et al. Apr 2018 B2
9950142 Eversull et al. Apr 2018 B2
9968452 Sheps et al. May 2018 B2
9974647 Ganesan et al. May 2018 B2
9974650 Nguyen-Thien-Nhon et al. May 2018 B2
9999504 Czyscon et al. Jun 2018 B2
10004599 Rabito et al. Jun 2018 B2
10016271 Morriss et al. Jul 2018 B2
10016272 Spence et al. Jul 2018 B2
10028832 Quill et al. Jul 2018 B2
10029037 Muller et al. Jul 2018 B2
10034747 Harewood Jul 2018 B2
10034749 Spence et al. Jul 2018 B2
10039637 Maimon et al. Aug 2018 B2
10045846 Bonyuet et al. Aug 2018 B2
10052198 Chau et al. Aug 2018 B2
10052199 Spence et al. Aug 2018 B2
10058318 Tegzes Aug 2018 B2
10058321 Sampson et al. Aug 2018 B2
10064719 Börtlein et al. Sep 2018 B2
10070954 Braido et al. Sep 2018 B2
10092400 Jimenez et al. Oct 2018 B2
10098734 Hoang Oct 2018 B2
10105217 Keränen Oct 2018 B2
10105224 Buchbinder et al. Oct 2018 B2
10130464 Meiri et al. Nov 2018 B2
10130471 Keränen et al. Nov 2018 B2
10143552 Wallace et al. Dec 2018 B2
10149759 Naor Dec 2018 B2
10172708 Anderson Jan 2019 B2
10172711 Keränen Jan 2019 B2
10179042 Braido et al. Jan 2019 B2
10195021 Keränen et al. Feb 2019 B2
10195025 Levi et al. Feb 2019 B2
10195027 Nasr Feb 2019 B2
10195028 Hosmer et al. Feb 2019 B2
10195029 Keränen Feb 2019 B2
10201418 Biadillah et al. Feb 2019 B2
10206775 Kovalsky et al. Feb 2019 B2
10213307 Dwork et al. Feb 2019 B2
10226330 Spence et al. Mar 2019 B2
10226334 Rowe et al. Mar 2019 B2
10226339 Spence et al. Mar 2019 B2
10238489 Conklin Mar 2019 B2
10251749 Zerkowski et al. Apr 2019 B2
10258464 Delaloye et al. Apr 2019 B2
10258468 Deem et al. Apr 2019 B2
10265169 Desrosiers et al. Apr 2019 B2
10271950 Neustadter Apr 2019 B2
10299917 Morriss et al. May 2019 B2
10299921 Dale et al. May 2019 B2
10314701 Von Segesser et al. Jun 2019 B2
10321988 Gorman et al. Jun 2019 B2
10321989 Keränen Jun 2019 B2
10327743 St. Goar et al. Jun 2019 B2
10327766 Zerkowski et al. Jun 2019 B2
10335277 Crisostomo et al. Jul 2019 B2
10338724 Zhao Jul 2019 B2
10350066 Cooper et al. Jul 2019 B2
10357351 Cooper et al. Jul 2019 B2
10357634 Simmons et al. Jul 2019 B2
10363130 Armer et al. Jul 2019 B2
10363131 Eidenschink et al. Jul 2019 B2
10368986 Gosal et al. Aug 2019 B2
10368990 Noe et al. Aug 2019 B2
10376266 Herman et al. Aug 2019 B2
10376360 Bruchman et al. Aug 2019 B2
10376363 Quadri et al. Aug 2019 B2
10398547 Li et al. Sep 2019 B2
10426608 Salahich et al. Oct 2019 B2
10433961 McLean Oct 2019 B2
10470881 Noe et al. Nov 2019 B2
10478291 Nguyen et al. Nov 2019 B2
10500048 Khairkhahan et al. Dec 2019 B2
10507104 Zhang et al. Dec 2019 B2
10512541 Zerkowski et al. Dec 2019 B2
10524901 Quadri et al. Jan 2020 B2
10548729 Zipory et al. Feb 2020 B2
10568737 Noe et al. Feb 2020 B2
10575951 Johnson et al. Mar 2020 B2
10603165 Maimon et al. Mar 2020 B2
10639154 Seguin May 2020 B2
10653524 Khairkhahan et al. May 2020 B2
10660753 Pham et al. May 2020 B2
10687938 Patel et al. Jun 2020 B2
10695160 Lashinski et al. Jun 2020 B2
10702386 Khairkhahan et al. Jul 2020 B2
10709552 Backus et al. Jul 2020 B2
10716662 Delaloye et al. Jul 2020 B2
10722352 Spence Jul 2020 B2
10722353 Levi Jul 2020 B2
10729542 Howard et al. Aug 2020 B2
10743991 Brown Aug 2020 B2
10751180 Schewel Aug 2020 B2
10751184 Reich et al. Aug 2020 B2
10765514 Iflah et al. Sep 2020 B2
10813749 Nguyen et al. Oct 2020 B2
10828153 Noe et al. Nov 2020 B2
10856970 Tuval et al. Dec 2020 B2
10869755 Granada et al. Dec 2020 B2
10888420 Bateman et al. Jan 2021 B2
10912644 Argento et al. Feb 2021 B2
10973629 Levi et al. Apr 2021 B2
10973630 Torrianni et al. Apr 2021 B2
11007057 Pham et al. May 2021 B2
11020221 Arcaro et al. Jun 2021 B2
11039922 Konno Jun 2021 B2
11147670 Hayoz Oct 2021 B2
11234818 Zerkowski Feb 2022 B2
11547563 Keränen Jan 2023 B2
11833034 Argento Dec 2023 B2
11877925 Manash Jan 2024 B2
20020173841 Ortiz et al. Nov 2002 A1
20030114913 Spenser et al. Jun 2003 A1
20030233142 Morales et al. Dec 2003 A1
20040039442 St. Goar et al. Feb 2004 A1
20040044350 Martin et al. Mar 2004 A1
20050137686 Salahieh et al. Jun 2005 A1
20050137687 Salahieh et al. Jun 2005 A1
20050137691 Salahieh et al. Jun 2005 A1
20050137694 Haug et al. Jun 2005 A1
20050137696 Salahieh et al. Jun 2005 A1
20050165344 Dobak, III Jul 2005 A1
20050240202 Shennib et al. Oct 2005 A1
20050277839 Alderman et al. Dec 2005 A1
20060009841 McGuckin, Jr. et al. Jan 2006 A1
20060052821 Abbot et al. Mar 2006 A1
20060074484 Huber Apr 2006 A1
20060178700 Quinn Aug 2006 A1
20060195134 Crittenden Aug 2006 A1
20060217762 Maahs et al. Sep 2006 A1
20060259136 Nguyen et al. Nov 2006 A1
20060293698 Douk Dec 2006 A1
20070027533 Douk Feb 2007 A1
20070038292 Danielpour Feb 2007 A1
20070051377 Douk et al. Mar 2007 A1
20070055206 To et al. Mar 2007 A1
20070118151 Davidson May 2007 A1
20070142907 Moaddeb et al. Jun 2007 A1
20070185572 Solem et al. Aug 2007 A1
20070255396 Douk et al. Nov 2007 A1
20070293724 Saadat et al. Dec 2007 A1
20070293943 Quinn Dec 2007 A1
20080004696 Vesely Jan 2008 A1
20080004697 Lichtenstein et al. Jan 2008 A1
20080200980 Robin et al. Aug 2008 A1
20080208327 Rowe Aug 2008 A1
20080208330 Keranen Aug 2008 A1
20080275503 Spence et al. Nov 2008 A1
20080275540 Wer Nov 2008 A1
20090088836 Bishop Apr 2009 A1
20090093826 Warder-Gabaldon Apr 2009 A1
20090138079 Tuval et al. May 2009 A1
20090157174 Yoganathan et al. Jun 2009 A1
20090192601 Rafiee et al. Jul 2009 A1
20090209950 Starksen Aug 2009 A1
20090222026 Rothstein et al. Sep 2009 A1
20090276040 Rowe et al. Nov 2009 A1
20100010520 Takahashi Jan 2010 A1
20100049239 McGuckin, Jr. et al. Feb 2010 A1
20100076497 Zwirkoski Mar 2010 A1
20100076549 Keidar et al. Mar 2010 A1
20100094406 Leprince et al. Apr 2010 A1
20100185172 Fabro Jul 2010 A1
20100198056 Fabro et al. Aug 2010 A1
20100198192 Serina et al. Aug 2010 A1
20100198208 Napp et al. Aug 2010 A1
20100217385 Thompson et al. Aug 2010 A1
20100312333 Navia et al. Dec 2010 A1
20110022164 Quinn et al. Jan 2011 A1
20110046600 Crank Feb 2011 A1
20110224785 Hacohen Sep 2011 A1
20110288637 De Marchena Nov 2011 A1
20110313515 Quadri et al. Dec 2011 A1
20110319989 Lane et al. Dec 2011 A1
20120022633 Olson et al. Jan 2012 A1
20120053680 Bolling et al. Mar 2012 A1
20120143316 Seguin et al. Jun 2012 A1
20120197388 Khairkhahan et al. Aug 2012 A1
20120203333 McGuckin, Jr. et al. Aug 2012 A1
20120221101 Moaddeb et al. Aug 2012 A1
20120277734 Geotz et al. Nov 2012 A1
20120277853 Rothstein Nov 2012 A1
20130006352 Yaron Jan 2013 A1
20130023985 Khairkhahan et al. Jan 2013 A1
20130035758 Seguin et al. Feb 2013 A1
20130079873 Migliazza et al. Mar 2013 A1
20130116779 Weber May 2013 A1
20130123912 Tung et al. May 2013 A1
20130172992 Gross et al. Jul 2013 A1
20130253643 Rolando et al. Sep 2013 A1
20130274873 Delaloye et al. Oct 2013 A1
20130325110 Khalil et al. Dec 2013 A1
20140005768 Thomas et al. Jan 2014 A1
20140031928 Murphy et al. Jan 2014 A1
20140081394 Keranen Mar 2014 A1
20140081154 Toth May 2014 A1
20140200649 Essinger et al. Jul 2014 A1
20140228943 Stigall et al. Aug 2014 A1
20140249621 Eidenschink Sep 2014 A1
20140257467 Lane et al. Sep 2014 A1
20140277382 Dolan Sep 2014 A1
20140277409 Börtlein et al. Sep 2014 A1
20140324163 Keränen et al. Oct 2014 A1
20150005764 Hanson et al. Jan 2015 A1
20150018876 Ewers et al. Jan 2015 A1
20150051709 Vasquez et al. Feb 2015 A1
20150134055 Spence et al. May 2015 A1
20150173897 Raanani et al. Jun 2015 A1
20150230921 Chau Aug 2015 A1
20150250480 Featherstone Sep 2015 A1
20150265403 Keränen Sep 2015 A1
20150272737 Dale et al. Oct 2015 A1
20150297346 Duffy et al. Oct 2015 A1
20150305863 Gray et al. Oct 2015 A1
20150328000 Ratz et al. Nov 2015 A1
20150335290 Hunter Nov 2015 A1
20150335426 Lim et al. Nov 2015 A1
20150351735 Keränen et al. Dec 2015 A1
20150351908 Keränen et al. Dec 2015 A1
20150351911 Keränen et al. Dec 2015 A1
20150374493 Yaron Dec 2015 A1
20160074165 Spence Mar 2016 A1
20160089126 Guo Mar 2016 A1
20160095705 Keränen Apr 2016 A1
20160113764 Sheahan et al. Apr 2016 A1
20160143689 Ditter May 2016 A1
20160143731 Backus et al. May 2016 A1
20160166380 Seguin et al. Jun 2016 A1
20160206853 Bolduc et al. Jul 2016 A1
20160228247 Maimon Aug 2016 A1
20160235526 Lashinski et al. Aug 2016 A1
20160235529 Ma et al. Aug 2016 A1
20160324637 Hlavka et al. Nov 2016 A1
20160324639 Nguyen et al. Nov 2016 A1
20160331523 Chau et al. Nov 2016 A1
20160346080 Righini Dec 2016 A1
20170007402 Zerkowski Jan 2017 A1
20170056163 Tayeb et al. Mar 2017 A1
20170071732 Conklin Mar 2017 A1
20170079790 Vidlund et al. Mar 2017 A1
20170112624 Patel Apr 2017 A1
20170119524 Salahleh et al. May 2017 A1
20170128203 Zhang et al. May 2017 A1
20170156723 Keating et al. Jun 2017 A1
20170165057 Morriss et al. Jun 2017 A9
20170189177 Schweich et al. Jul 2017 A1
20170216025 Nitzan et al. Aug 2017 A1
20170245850 Call et al. Aug 2017 A1
20170258585 Marquez et al. Sep 2017 A1
20170273788 O'Carroll et al. Sep 2017 A1
20170273789 Yaron et al. Sep 2017 A1
20170281341 Lim et al. Oct 2017 A1
20170311937 Bambury et al. Nov 2017 A1
20170348099 Mendelson et al. Dec 2017 A1
20180049873 Manash et al. Feb 2018 A1
20180055628 Patel et al. Mar 2018 A1
20180092763 Dagan et al. Apr 2018 A1
20180110622 Gregg et al. Apr 2018 A1
20180116790 Ratz et al. May 2018 A1
20180133003 Levi May 2018 A1
20180177592 Benichou et al. Jun 2018 A1
20180177594 Patel Jun 2018 A1
20180206982 Haivatov et al. Jul 2018 A1
20180206986 Noe et al. Jul 2018 A1
20180206992 Brown Jul 2018 A1
20180207395 Bulman et al. Jul 2018 A1
20180214267 Lally et al. Aug 2018 A1
20180214270 Subramanian et al. Aug 2018 A1
20180221014 Darabian Aug 2018 A1
20180228608 Sheps et al. Aug 2018 A1
20180228610 Lashinski et al. Aug 2018 A1
20180235443 Smith et al. Aug 2018 A1
20180250126 O'Connor et al. Sep 2018 A1
20180250132 Ketai et al. Sep 2018 A1
20180263764 Manash et al. Sep 2018 A1
20180280171 Gloss et al. Oct 2018 A1
20180289473 Rajagopal et al. Oct 2018 A1
20180289474 Rajagopal et al. Oct 2018 A1
20180289478 Quill Oct 2018 A1
20180289480 D'ambra et al. Oct 2018 A1
20180289485 Rajagopal et al. Oct 2018 A1
20180296335 Miyashiro Oct 2018 A1
20180296338 Rabito et al. Oct 2018 A1
20180318079 Patel et al. Nov 2018 A1
20180325665 Gurovich et al. Nov 2018 A1
20180333259 Dibie Nov 2018 A1
20180344303 Bambury et al. Dec 2018 A1
20180344454 Mauch et al. Dec 2018 A1
20180344459 Spence et al. Dec 2018 A1
20180344971 Suzuki Dec 2018 A1
20180360600 Zhuang et al. Dec 2018 A1
20180368830 O'Carroll et al. Dec 2018 A1
20190000615 Tayeb et al. Jan 2019 A1
20190000625 O'Carroll et al. Jan 2019 A1
20190008635 Francis et al. Jan 2019 A1
20190008639 Landon et al. Jan 2019 A1
20190008640 Cooper et al. Jan 2019 A1
20190015205 Rajagopal et al. Jan 2019 A1
20190021859 O'Carrol et al. Jan 2019 A1
20190046315 Gao et al. Feb 2019 A1
20190053894 Levi et al. Feb 2019 A1
20190053895 Levi Feb 2019 A1
20190053898 Maimon et al. Feb 2019 A1
20190053899 Levi Feb 2019 A1
20190053903 Rohl et al. Feb 2019 A1
20190060068 Cope et al. Feb 2019 A1
20190060069 Maimon et al. Feb 2019 A1
20190060071 Lane et al. Feb 2019 A1
20190076244 Yohanan et al. Mar 2019 A1
20190076664 Ollivier Mar 2019 A1
20190117392 Quadri et al. Apr 2019 A1
20190133756 Zhang et al. May 2019 A1
20190133757 Zhang et al. May 2019 A1
20190142589 Basude May 2019 A1
20190159770 Rohl et al. May 2019 A1
20190160292 Peichel et al. May 2019 A1
20190167425 Reich et al. Jun 2019 A1
20190183649 Allen et al. Jun 2019 A1
20190192288 Levi et al. Jun 2019 A1
20190192296 Schwartz et al. Jun 2019 A1
20190201191 McLean et al. Jul 2019 A1
20190209311 Zhang et al. Jul 2019 A1
20190209312 Zhang et al. Jul 2019 A1
20190209313 Zhang et al. Jul 2019 A1
20190209314 Zhang et al. Jul 2019 A1
20190209315 Zhang et al. Jul 2019 A1
20190209316 Zhang et al. Jul 2019 A1
20190209317 Zhang et al. Jul 2019 A1
20190209318 Zhang et al. Jul 2019 A1
20190209320 Draster et al. Jul 2019 A1
20190231520 Desrosiers et al. Aug 2019 A1
20190240023 Spence et al. Aug 2019 A1
20190246916 Kuraguntla et al. Aug 2019 A1
20190254816 Anderson et al. Aug 2019 A1
20190261995 Goldfarb et al. Aug 2019 A1
20190261996 Goldfarb et al. Aug 2019 A1
20190261997 Goldfarb et al. Aug 2019 A1
20190262129 Cooper et al. Aug 2019 A1
20190282237 Goldfarb et al. Sep 2019 A1
20190328518 Neumann Oct 2019 A1
20190336282 Christianson et al. Nov 2019 A1
20190343625 Gharib et al. Nov 2019 A1
20190365530 Hoang et al. Dec 2019 A1
20190374337 Zamani et al. Dec 2019 A1
20190374342 Gregg et al. Dec 2019 A1
20200000579 Manash et al. Jan 2020 A1
20200000586 Tian et al. Jan 2020 A1
20200008936 Cheema et al. Jan 2020 A1
20200022811 Griswold et al. Jan 2020 A1
20200054453 Zerkowski et al. Feb 2020 A1
20200060813 Nguyen et al. Feb 2020 A1
20200060820 Ben-Zvi et al. Feb 2020 A1
20200060852 Argento et al. Feb 2020 A1
20200078000 Rajagopal et al. Mar 2020 A1
20200093601 Neustadter Mar 2020 A1
20200107930 Argento Apr 2020 A1
20200107932 Rabito et al. Apr 2020 A1
20200107933 Oba Apr 2020 A1
20200113586 Karasic et al. Apr 2020 A1
20200113685 Miller et al. Apr 2020 A1
20200113696 Ekvall et al. Apr 2020 A1
20200138575 Tuval May 2020 A1
20200139082 Matlock May 2020 A1
20200178977 Coleman et al. Jun 2020 A1
20200188107 Gloss et al. Jun 2020 A1
20200205800 Gilmore et al. Jul 2020 A1
20200205969 Hacohen Jul 2020 A1
20200205974 Zerkowski et al. Jul 2020 A1
20200205975 Khairkhahan Jul 2020 A1
20200205979 O'Carroll et al. Jul 2020 A1
20200214708 Sharma Jul 2020 A1
20200229806 Goldfarb et al. Jul 2020 A1
20200229918 Pham et al. Jul 2020 A1
20200261220 Argento Aug 2020 A1
20200275921 Gilmore et al. Sep 2020 A1
20200276017 Subramanian et al. Sep 2020 A1
20200297489 Bishop et al. Sep 2020 A1
20200297491 Argento et al. Sep 2020 A1
20200345492 Patel Nov 2020 A1
20200352705 Heneghan et al. Nov 2020 A1
20200352706 Campbell Nov 2020 A1
20200360139 Hammer et al. Nov 2020 A1
20210022854 Zhao et al. Jan 2021 A1
20210022860 Lally et al. Jan 2021 A1
20210030536 Kaleta Feb 2021 A1
20210121289 Bruchman et al. Apr 2021 A1
20210128297 Braido et al. May 2021 A1
20210145573 Dasi et al. May 2021 A1
20210154009 Argento May 2021 A1
20210161688 Shahriani Jun 2021 A1
20210177583 Colavito et al. Jun 2021 A1
20210177584 Levi et al. Jun 2021 A1
20210177587 Braido Jun 2021 A1
20210186689 Eidenschink et al. Jun 2021 A1
20210228343 Scheinblum et al. Jul 2021 A1
20210378823 Argento et al. Dec 2021 A1
20210401572 Nasar et al. Dec 2021 A1
20220054261 Argento et al. Feb 2022 A1
20220175522 Salahieh Jun 2022 A1
20220387755 Higgins Dec 2022 A1
20220401214 Saul Dec 2022 A1
20230044256 Salahieh Feb 2023 A1
20240041598 Argento Feb 2024 A1
20240285396 Schwartz Aug 2024 A1
20240293217 Cartledge Sep 2024 A1
Foreign Referenced Citations (139)
Number Date Country
2012261727 Oct 2015 AU
2019246822 Aug 2020 AU
2020227034 Sep 2020 AU
PI0820603 Jun 2020 BR
2979817 Sep 2016 CA
2954826 Oct 2019 CA
103764216 Apr 2014 CN
103974670 Aug 2014 CN
105358098 Feb 2016 CN
107690323 Feb 2018 CN
111110401 May 2020 CN
111110403 May 2020 CN
108601655 Jun 2020 CN
111265335 Jun 2020 CN
111278389 Jun 2020 CN
111329541 Jun 2020 CN
19857887 May 2005 DE
102014102650 Sep 2015 DE
1105181 Feb 2004 EP
1432369 Feb 2008 EP
2374415 Oct 2011 EP
2907479 Aug 2015 EP
3037064 Jun 2016 EP
3158975 Apr 2017 EP
3342355 Jul 2018 EP
3395296 Oct 2018 EP
3406225 Nov 2018 EP
3417831 Dec 2018 EP
3476366 May 2019 EP
3482718 May 2019 EP
2637607 Oct 2019 EP
3554424 Oct 2019 EP
3244809 Feb 2020 EP
3639792 Apr 2020 EP
3417831 May 2020 EP
3649963 May 2020 EP
2072027 Jun 2020 EP
3672528 Jul 2020 EP
344104581 Jul 2020 EP
3554423 Aug 2020 EP
3107498 Sep 2020 EP
3570782 Sep 2020 EP
3700467 Sep 2020 EP
3705090 Sep 2020 EP
3782585 Feb 2021 EP
H08131551 May 1996 JP
2004154177 Jun 2004 JP
2008018139 Jan 2008 JP
2011506017 Mar 2011 JP
2012531270 Dec 2012 JP
2020515375 May 2020 JP
2020517379 Jun 2020 JP
2020520729 Jul 2020 JP
6735294 Aug 2020 JP
2020032237 Mar 2020 KR
2020033349 Mar 2020 KR
2020033350 Mar 2020 KR
202027694 Aug 2020 TW
WO2007007873 Jan 2007 WO
WO2007081820 Jul 2007 WO
WO2010141847 Dec 2010 WO
WO2011025945 Mar 2011 WO
WO2012087842 Jun 2012 WO
WO2012145545 Oct 2012 WO
WO2013190910 Dec 2013 WO
WO2015127264 Aug 2015 WO
WO2015173609 Nov 2015 WO
WO2015195823 Dec 2015 WO
WO2016052145 Apr 2016 WO
WO2016117169 Jul 2016 WO
WO2016183485 Nov 2016 WO
WO2017121193 Jul 2017 WO
WO2017151566 Sep 2017 WO
WO2017214098 Dec 2017 WO
WO2018025260 Feb 2018 WO
WO2018039561 Mar 2018 WO
WO2018039589 Mar 2018 WO
WO2018112429 Jun 2018 WO
WO2018119304 Jun 2018 WO
WO2018178966 Oct 2018 WO
WO2018178967 Oct 2018 WO
WO2018187390 Oct 2018 WO
WO2018192197 Oct 2018 WO
WO2019010370 Jan 2019 WO
WO2019036592 Feb 2019 WO
WO2019062366 Apr 2019 WO
WO2019081777 May 2019 WO
WO2019086958 May 2019 WO
WO2019102484 May 2019 WO
WO2019116369 Jun 2019 WO
WO2019118371 Jun 2019 WO
WO2019135011 Jul 2019 WO
WO2019135028 Jul 2019 WO
WO2019144036 Jul 2019 WO
WO2019147504 Aug 2019 WO
WO2019147846 Aug 2019 WO
WO2019154124 Aug 2019 WO
WO2019164516 Aug 2019 WO
WO2019195860 Oct 2019 WO
WO2019209927 Oct 2019 WO
WO2019222694 Nov 2019 WO
WO2019241777 Dec 2019 WO
WO2020051147 Mar 2020 WO
WO2020051591 Mar 2020 WO
WO2020072199 Apr 2020 WO
WO2020072201 Apr 2020 WO
WO2020073050 Apr 2020 WO
WO2020123719 Jun 2020 WO
WO2020157018 Aug 2020 WO
WO2020163112 Aug 2020 WO
WO2020236830 Nov 2020 WO
WO2020247907 Dec 2020 WO
WO2021021482 Feb 2021 WO
WO2021028867 Feb 2021 WO
WO2021034497 Feb 2021 WO
WO2021086850 May 2021 WO
WO2021087400 May 2021 WO
WO2021091754 May 2021 WO
WO2021113143 Jun 2021 WO
WO2021178560 Sep 2021 WO
WO2021183610 Sep 2021 WO
WO2021207545 Oct 2021 WO
WO2021257278 Dec 2021 WO
WO2021257722 Dec 2021 WO
WO2022010974 Jan 2022 WO
WO2022046678 Mar 2022 WO
WO2022047095 Mar 2022 WO
WO2022047160 Mar 2022 WO
WO2022047274 Mar 2022 WO
WO2022047393 Mar 2022 WO
WO2022047395 Mar 2022 WO
WO2022066713 Mar 2022 WO
WO2022066720 Mar 2022 WO
WO2022174160 Aug 2022 WO
WO2022271851 Dec 2022 WO
WO2023034936 Mar 2023 WO
WO2023049625 Mar 2023 WO
WO2023064910 Apr 2023 WO
WO2022204138 Sep 2024 WO
Non-Patent Literature Citations (27)
Entry
Saul; U.S. Appl. No. 17/773,193 entitled “Prosthetic cardiac valve delivery devices, systems, and methods,” filed Apr. 29, 2022.
Schaefer; Large heart valves—small heart valves; ISMAAP; Oct. 19, 2015; 5 pages; retrieved from the internet (https://www.ismaap.org/condition-detail/large-heart-valves-small-heart-valves/) on Mar. 21, 2023.
Argento et al.; U.S. Appl. No. 18/002,219 entitled “Minimal frame prosthetic cardiac valve delivery devices, systems, and methods,” filed Dec. 16, 2022.
Adamek-Bowers et al.; U.S. Appl. No. 18/043,458 entitled “Prosthetic valve delivery system,” filed Feb. 28, 2023.
Backus et al.; U.S. Appl. No. 18/004,609 entitled “Valve delivery system,” filed Jan. 6, 2023.
Mulcahy et al.; U.S. Appl. No. 18/043,480 entitled “Prosthetic cardiac valve delivery devices, systems, and methods,” filed Feb. 28, 2023.
Adamek-Bowers et al.; U.S. Appl. No. 18/043,499 entitled “Interface for prosthetic cardiac valve and delivery systems,” filed Feb. 28, 2023.
Salahieh et al.; U.S. Appl. No. 18/043,519 entitled “Flared prosthetic cardiac valve delivery devices and systems,” filed Feb. 28, 2023.
Scott et al.; U.S. Appl. No. 18/043,526 entitled “Access sheath for prosthetic cardiac valve delivery systems,” filed Feb. 28, 2023.
Yang et al.; U.S. Appl. No. 18/043,542 entitled “Anchor for prosthetic cardiac valve devices,” filed Feb. 28, 2023.
Argento et al.; U.S. Appl. No. 18/246,307 entitled “Systems, methods, and devices for expandable sensors,” filed Mar. 22, 2023.
Argento et al.; U.S. Appl. No. 18/246,311 entitled “Prosthetic cardiac valve sensor devices, systems, and methods with imaging,” filed Mar. 22, 2023.
Westaby et al.; Adult human valve dimensions and their surgical significance; The American Journal of Cardiology; 53(4); pp. 552-556; Feb. 1984.
Salahieh et al.; U.S. Appl. No. 17/543,555 entitled “Flared prosthetic cardiac valve delivery devices and systems,” filed Dec. 6, 2021.
Yang et al.; U.S. Appl. No. 17/651,040 entitled “Anchor for prosthetic cardiac valve delivery devices and systems”, filed Feb. 14, 2022.
Argento et al.; U.S. Appl. No. 17/931,408 entitled “Prosthetic cardiac valve devices, systems, and methods,” filed Sep. 12, 2022.
Argento; U.S. Appl. No. 17/906,216 entitled “Prosthetic cardiac valve devices, systems, and methods,” filed Sep. 13, 2022.
Argento et al.; U.S. Appl. No. 17/905,556 entitled “Prosthetic cardiac valve devices, systems, and methods,” filed Sep. 2, 2022.
Boyd et al.; U.S. Appl. No. 17/995,776 entitled “Valve delivery system”, filed Oct. 7, 2022.
Argento et al.; U.S. Appl. No. 18/185,330 entitled “Prosthetic cardiac valve devices, systems, and methods,” filed Mar. 16, 2023.
Adamek-Bowers et al.; U.S. Appl. No. 18/255,763 entitled “Mitral valve implants,” filed Jun. 2, 2023.
Argento et al.; U.S. Appl. No. 18/494,520 entitled “Prosthetic cardiac valve devices, systems, and methods,” filed Oct. 25, 2023.
Mulcahy et al.; U.S. Appl. No. 18/573,816 entitled “Prosthetic cardiac valve delivery devices, systems, and methods,” filed Dec. 22, 2023.
Boyd et al.; U.S. Appl. No. 18/688,735 entitled “Guide catheter for prosthetic cardiac valve delivery systems, ” filed Mar. 1, 2024.
Adamek-Bowers et al.; U.S. Appl. No. 18/693,856 entitled “Tether delivery of cardiac valve,” filed Mar. 20, 2024.
Yang et al.; U.S. Appl. No. 18/700,621 entitled “Cardiac valve prosthesis delivery system and methods of use,” filed Apr. 11, 2024.
Masterclass; Knit vs. Woven: Learn How to Identify the Two Fabric Types; Jun. 7, 2021; 13 pages; retrieved from the internet (https://www.masterclass.com/articles/knit-vs-woven-learn-how-to-identify-the-two-fabric-types) on Nov. 15, 2024.
Related Publications (1)
Number Date Country
20230044256 A1 Feb 2023 US
Provisional Applications (1)
Number Date Country
63164514 Mar 2021 US